Candel Therapeutics, Inc is a clinical stage biopharmaceutical company. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The Company also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)